{ }
001122334455554433221100
001122334455554433221100

GSK Partners with Muna Therapeutics to Advance Alzheimer's Drug Development

Muna Therapeutics has partnered with GSK to explore new Alzheimer’s drug targets by analyzing brain tissue samples from various sources, including healthy individuals and Alzheimer’s patients. GSK will invest €33.5 million upfront, with potential milestone payments of up to €140 million for each target identified. This collaboration marks GSK's renewed focus on neuroscience after a decade-long hiatus, leveraging Muna's technology to advance drug development in neurodegenerative diseases.

GSK reports positive Phase 3 results for chronic nasal condition drug

GSK announced positive results from two Phase 3 trials of its antibody drug depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP), showing significant suppression of nasal polyp growth and improved nasal obstruction compared to placebo. The drug, which targets IL-5, is also being studied for asthma and other inflammatory diseases, with potential peak annual sales exceeding £3 billion if approved. Detailed trial results will be presented at an upcoming scientific congress.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Machinary - Dashboard

Client connection lost

Please check your connection. We try to reconnect...

Server connection lost

If our server is updating to a new version, please wait a moment before the service is available again.

Connection refused

All connection attempts have been rejected. This is most likely due to network problems or server problems.